Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURATE.AI in Multiple Myeloma
NCT03759093Phase 3Unknown
- Sponsor
- National University Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by National University Hospital. Primary endpoint: Response rate at 16 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT03759093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759093.